ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

DCE Reorganization Planned To Stem Departures, Stabilize

March 24, 1995

DePinho Explains Tenure Decision,Professors Dispute Key Details

May 30, 2014

In Brief: Cancer Act, Accelerated Progress, ACS President Says; Scanners Scapegoats, EMI Chief Claimes

April 7, 1978

RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment

September 27, 2013

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

February 24, 2006

Oral Therapy Sorafenib Improves Survival Of Advanced Liver Cancer In Study

June 29, 2007